October 15th 2025
This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development or orphan drugs.
Indian Pharma Is Committed to the Future, Says Biocon Managing Director
June 2nd 2016Investment in talent and infrastructure, more quality-by-design skills, and increased communication with global regulators will be needed to combat compliance issues at API and drug manufacturing facilities in India.